All‐cause mortality ( · adult patients after liver transplantation.
Prostaglandin showed no clear difference in all‐cause mortality ( compared with placebo or standard care (low certainty).
1 finding from 1 review
Serious adverse eventsc ( · adult patients after liver transplantation.
Prostaglandin showed no clear difference in serious adverse eventsc ( compared with placebo or standard care (low certainty).
1 finding from 1 review
Health‐related quality of life · adult patients after liver transplantation.
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Liver retransplantation ( · adult patients after liver transplantation.
Prostaglandin showed no clear difference in liver retransplantation ( compared with placebo or standard care (low certainty).
1 finding from 1 review
Primary non‐function of the allograft · adult patients after liver transplantation.
Prostaglandin showed no clear difference in primary non‐function of the allograft (at up to 1 month) compared with placebo or standard care (low certainty).
1 finding from 1 review
Acute kidney failure requiring dialysis ( · adult patients after liver transplantation.
Prostaglandin may leads to lower acute kidney failure requiring dialysis ( compared with placebo or standard care (low certainty).
1 finding from 1 review
Adverse events considered non‐serious · adult patients after liver transplantation.
It is very uncertain whether prostaglandin changes adverse events considered non‐serious ( compared with placebo or standard care (very low certainty).
1 finding from 1 review
Oral mucositis (moderate to severe) · Patients with cancer receiving radiotherapy, chemotherapy or targeted therapies
Prostaglandin showed no clear difference in oral mucositis (moderate to severe) compared with placebo; GRADE not reported.
1 finding from 1 review
Failure to achieve complete abortion · women undergoing first trimester abortion
Mifepristone (600 mg) plus prostaglandin showed no clear difference in failure to achieve complete abortion compared with mifepristone (200 mg) plus prostaglandin (moderate certainty).
1 finding from 1 review
Nausea · women undergoing first trimester abortion
Mifepristone (600 mg) plus prostaglandin showed no clear difference in nausea compared with mifepristone (200 mg) plus prostaglandin (moderate certainty).
1 finding from 1 review
Women's dissatisfaction with the procedure · women undergoing first trimester abortion
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Blood transfusion · women undergoing first trimester abortion
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Failure to achieve complete abortion · women undergoing first trimester abortion
Prostaglandin alone may leads to higher failure to achieve complete abortion compared with combined regimen (low certainty).
1 finding from 1 review
Nausea · women undergoing first trimester abortion
Prostaglandin alone showed no clear difference in nausea compared with combined regimen (low certainty).
1 finding from 1 review
Women's dissatisfaction with the procedure · women undergoing first trimester abortion
Prostaglandin alone showed no clear difference in women's dissatisfaction with the procedure compared with combined regimen (low certainty).
1 finding from 1 review
Blood transfusion · women undergoing first trimester abortion
Prostaglandin alone showed no clear difference in blood transfusion compared with combined regimen (low certainty).
1 finding from 1 review
Glaucoma progression at 12 months, measured by additional visual field defects · people with primary open‐angle glaucoma or ocular hypertension
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Difference in mean IOP from baseline at < 6 months · people with primary open‐angle glaucoma or ocular hypertension
1 finding from 1 review
Glaucoma progression at 12 months, defined by anatomic (structural) criteriab · people with primary open‐angle glaucoma or ocular hypertension
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Patient‐reported outcome at the longest · people with primary open‐angle glaucoma or ocular hypertension
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found